Cell MedX Corp Stock OTC Bulletin Board
Equities
US15115X1072
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-15 | Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
03-12 | Cell MedX Corp. announced that it has received $0.075 million in funding | CI |
Sales 2022 | 0.01 0.01 | Sales 2023 | 0 0 | Capitalization | 6.29K 8.59K |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 1,135,153,669 x |
Net Debt 2022 | 592K 809K | Net Debt 2023 | 903K 1.23M | EV / Sales 2023 | 329,116,944 x |
P/E ratio 2022 |
-9.01
x | P/E ratio 2023 |
-0.01
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20.34% |
Managers | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12-11 |
Yanika Silina
DFI | Director of Finance/CFO | 46 | 14-11-23 |
George Adams
CHM | Chairman | 76 | 18-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12-11 |
Dwayne Yaretz
BRD | Director/Board Member | 63 | 22-04-26 |
Joao da Costa
BRD | Director/Board Member | 59 | 20-06-07 |
1st Jan change | Capi. | |
---|---|---|
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |